[{"id":"4ac96ad9-6616-4fe1-9a5c-716eb6d6ecd4","acronym":"TQA3334-Ⅰ-02","url":"https://clinicaltrials.gov/study/NCT04273815","created_at":"2021-01-18T20:45:32.940Z","updated_at":"2024-07-02T16:36:43.495Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets","source_id_and_acronym":"NCT04273815 - TQA3334-Ⅰ-02","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK positive","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • AL-034"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 01/31/2021","study_completion_date":" 01/31/2021","last_update_posted":"2020-07-08"}]